Literature DB >> 9624739

Use of immunodeficient mice in metastasis research.

B S Mitchell1, U Schumacher.   

Abstract

One of the major clinical problems facing the western world is how to stem the tide of deaths from metastasising malignancies. Despite some progress in diagnosis and treatment, the death rate from major clinically important tumours, such as lung, breast and colon cancer, shows no signs of abating. This therapeutic failure is due to tumour metastasis, for which no treatment options are available. Effort has been made to find valid animal models in which the metastatic process can be studied, and in which putative treatments can be evaluated. This review discusses some of the approaches used in creating these models, and focuses on current work using the severe combined immunodeficient (SCID) mouse.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9624739

Source DB:  PubMed          Journal:  Br J Biomed Sci        ISSN: 0967-4845            Impact factor:   3.829


  3 in total

1.  Increased number of microglia in the brain of severe combined immunodeficient (SCID) mice.

Authors:  Dietrich E Lorke; Chi Wang Ip; Udo Schumacher
Journal:  Histochem Cell Biol       Date:  2008-07-04       Impact factor: 4.304

2.  Expression of sphingosine-1-phosphate receptors and lysophosphatidic acid receptors on cultured and xenografted human colon, breast, melanoma, and lung tumor cells.

Authors:  Reinhard Müller; Christoph Berliner; Jessica Leptin; Daniel Pörtner; Wojciech Bialecki; Burkhard Kleuser; Udo Schumacher; Novica M Milićević
Journal:  Tumour Biol       Date:  2010-05-18

3.  Drosophila homologue of Diaphanous 1 (DIAPH1) controls the metastatic potential of colon cancer cells by regulating microtubule-dependent adhesion.

Authors:  Yuan-Na Lin; Ridhirama Bhuwania; Kira Gromova; Antonio Virgilio Failla; Tobias Lange; Kristoffer Riecken; Stefan Linder; Matthias Kneussel; Jakob R Izbicki; Sabine Windhorst
Journal:  Oncotarget       Date:  2015-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.